Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis

References

• De Nunzio C, Roehrborn CG, Andersson K-E, et al. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus. 2017;3(4-5):352–363.
   PubMedGoogle Scholar
• Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia – what do we know? BJU Int. 2021;127(4):389–311.
   PubMed Web of Science ®Google Scholar
• Larønningen S, Ferlay J, Bray F, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, version 9.1. Nord Cancer Incid Mortality, Preval Surviv Nord Countries, Version 91. 2021.
   Google Scholar
• Kvåle R, Myklebust T, Engholm G, et al. Prostate and breast cancer in four Nordic countries: a comparison of incidence and mortality trends across countries and age groups 1975–2013. Int J Cancer. 2017;141(11):2228–2242.
   PubMed Web of Science ®Google Scholar
• Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2016;67:137–151.
   PubMed Web of Science ®Google Scholar
• Ørsted DD, Bojesen SE, Nielsen SF, et al. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol. 2011;60(4):691–698.
   PubMed Web of Science ®Google Scholar
• Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10(1):49–54.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004;101(10 Suppl):2371–2490. [cited 2021 Dec 9]
   PubMed Web of Science ®Google Scholar
• Armenian H, Lilienfeld A, Diamond E, et al. Relation between benign prostatic hyperplasia and cancer of the prostate. Lancet. 1974;304(7873):115–117.
   Google Scholar
• Hammarsten J, Högstedt B. Calculated fast-growing benign prostatic hyperplasia. Scand J Urol Nephrol. 2002;36(5):330–338.
   PubMed Web of Science ®Google Scholar
• Chokkalingam AP, Nyrén O, Johansson J-E, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003;98(8):1727–1734.
   PubMed Web of Science ®Google Scholar
• Bengtsen MB, Farkas DK, Borre M, et al. Acute urinary retention and risk of cancer: population based Danish cohort study. BMJ 2021;375:n2305.
   PubMed Web of Science ®Google Scholar
• Gaither TW, Awad MA, Osterberg EC, et al. The natural history of erectile dysfunction after prostatic radiotherapy: a systematic review and meta-analysis. J Sex Med 2017;14(9):1071–1078.
   PubMed Web of Science ®Google Scholar
• Plym A, Folkvaljon Y, Garmo H, et al. Drug prescription for erectile dysfunction before and after diagnosis of localized prostate cancer. J Sex Med. 2014;11(8):2100–2108.
   PubMed Web of Science ®Google Scholar
• Haahr MK, Azawi NH, Andersen LG, et al. A retrospective study of erectile function and use of erectile aids in prostate cancer patients after radical prostatectomy in Denmark. Sex Med. 2017;5(3):e156–e162.
   PubMed Web of Science ®Google Scholar
• Carlsson S, Drevin L, Loeb S, et al. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int. 2016;117(6B):E36–E45.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Tammela TLJ, Määttänen L, et al. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer. 2009;101(5):843–848.
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Karppa EK, Taari K, et al. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. Int J Cancer. 2016;138(12):2820–2828.
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang Y, Gu Y, et al. Prostate cancer risk and prognostic influence among users of 5-alpha-reductase inhibitors and alpha-blockers: a systematic review and meta-analysis. Urology. 2020;145:216–223.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22–25.
   PubMed Web of Science ®Google Scholar
• Gjerstorff ML. The Danish cancer registry. Scand J Public Health. 2011;39(7 Suppl):42–45.
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sørensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health. 2011;39(7 Suppl):38–41.
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health. WHO collaborating Centre for drug statistics methodology, guidelines for ATC classification and DDD assignment 2022. Oslo (Norway): WHO Collaborating Centre for Drug Statistics Methodology; 2021. [cited 2022 Feb 15]. Available from: http://www.whocc.no/atcddd/.
   Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health 2011;39(7 Suppl):30–33.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Fode M, Sønksen J. Sexual function in elderly men receiving Androgen Deprivation Therapy (ADT). Sex Med Rev. 2014;2(1):36–46.
   PubMedGoogle Scholar
• Larsen SB, Dehlendorff C, Skriver C, et al. Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. Cancer Causes Control. 2022;33(3):417–428.
   PubMed Web of Science ®Google Scholar
• Dansk Urologisk Cancer Gruppe. Årsrapport 2018 [Internet]. 2019 [cited 2021 Sep 7]. Available from: www.rkkp.dk.
   Google Scholar
• Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373(9660):301–308.
   PubMed Web of Science ®Google Scholar
• Klarskov LL, Klarskov P, Mommsen S, et al. Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study. Scand J Urol Nephrol. 2012;46(1):37–43.
   PubMed Web of Science ®Google Scholar